IPP Bureau

21.4 lakh TB cases notified in India in 2021
21.4 lakh TB cases notified in India in 2021

By IPP Bureau - October 30, 2022

Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today

Recent launch of 5G will bring a new revolution in digital healthcare: Dr. Singh
Recent launch of 5G will bring a new revolution in digital healthcare: Dr. Singh

By IPP Bureau - October 30, 2022

India will become a digital health leader, as we have the world’s best technical manpower required and our data is the cheapest in the world, approaching 100 percent coverage

Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr
Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr

By IPP Bureau - October 30, 2022

The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track

Mandaviya addresses Second G20 Health Ministers Meet
Mandaviya addresses Second G20 Health Ministers Meet

By IPP Bureau - October 28, 2022

He also encouraged all G20 members to contribute their public keys to the proposed Global Federated Public Trust Directory for ensuring seamless worldwide mobility of people and goods

Centre deploys high-level team to Kerala to investigate Avian Influenza Outbreak
Centre deploys high-level team to Kerala to investigate Avian Influenza Outbreak

By IPP Bureau - October 28, 2022

The team will also assist the state health departments in terms of public health measures, management guidelines and protocols to manage the increasing cases of Avian Influenza

Vimta Labs posts consolidated PAT of Rs. 13.21 crores in Q2FY23
Vimta Labs posts consolidated PAT of Rs. 13.21 crores in Q2FY23

By IPP Bureau - October 28, 2022

The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022

ProBioGen co-develops new Freedom ExpiCHO-S cell line development kit
ProBioGen co-develops new Freedom ExpiCHO-S cell line development kit

By IPP Bureau - October 28, 2022

It allows users to generate cell lines suitable for clinical development without their own starter cells, vectors or prior experience in the field.

Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset
Ardigen supports JUMP-CP Consortium scaling up image-based drug discovery with the world’s largest public Cell Painting dataset

By IPP Bureau - October 28, 2022

The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set

Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr
Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr

By IPP Bureau - October 27, 2022

Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr

Dabur India posts consolidated Q2 FY2023 PAT at Rs. 490.06 Cr
Dabur India posts consolidated Q2 FY2023 PAT at Rs. 490.06 Cr

By IPP Bureau - October 27, 2022

The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022

Zydus gets USFDA’s approval for Ketorolac Tromethamine Tablets
Zydus gets USFDA’s approval for Ketorolac Tromethamine Tablets

By IPP Bureau - October 27, 2022

Ketorolac Tromethamine Tablets are indicated to relieve moderately severe pain, usually after surgery.

USFDA Issues a CRL for the Biologics License Application for Insulin Aspart
USFDA Issues a CRL for the Biologics License Application for Insulin Aspart

By IPP Bureau - October 27, 2022

The CRL did not identify any outstanding scientific issues with the product.

Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial
Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial

By IPP Bureau - October 27, 2022

Results reinforce commitment to next-generation oral SERD development programme

Robert M. Davis is the new Chairman of Merck
Robert M. Davis is the new Chairman of Merck

By IPP Bureau - October 27, 2022

Frazier led the company for 10 years as President and Chief Executive Officer, from 2011 through 2021.

ERES IV acquires a majority stake in Oncodesign Services
ERES IV acquires a majority stake in Oncodesign Services

By IPP Bureau - October 27, 2022

Oncodesign Services (ODS ), with 600 clients in 33 countries and 227 employees worldwide, provides services from target identification to hit-to-lead and lead optimization through to IND filing.

Latest Stories

Interviews

Packaging